bloated stomach semaglutide on Semaglutide: A New Hope for Sustainable Weight Management Weight Loss & Nutrition Management

Wang R, Lu L, Guo Y, Lin F, Chen H, Chen W, et al

Tirzepatide is a single-molecule dual GIP and GLP-1 receptor agonist

While Foundayo is unlikely to contribute meaningfully to second-quarter revenues given its recent launch, its initial uptake and management's commentary will provide important insights into its long-term commercial potential and global rollout plans

Subscribe to Scientific American for more up-to-date and in-depth science news

Comparative Effectiveness: Studies are underway to compare semaglutide with other GLP-1 receptor agonists and newer combination therapies to achieve optimal patient outcomes

In addition to agonists only target to GLP-1 receptors, agonists with multiple targets now are being developed